# RPL5 deficiency-induced ribosomal stress targets a select subset of proteins and inhibits the PI3K-Akt-mTOR signaling pathway to eradicate leukemia stem cells

**Authors:** Xiaofei He, Daijiao Ye, Jiayao He, Gangfeng Ding, Zihan Lin, Yaqian Qin, Bin Zhou, Liuzhi Shi, Xuanyu Yu, Chen Meng, Min Li, Chongyun Xing, Shenmeng Gao

PMC · DOI: 10.1038/s41419-025-08379-1 · Cell Death & Disease · 2025-12-18

## TL;DR

This study shows that reducing RPL5 in leukemia stem cells causes cellular stress and disrupts a key signaling pathway, leading to the elimination of these cancerous cells.

## Contribution

The study reveals that RPL5 deficiency induces ribosomal stress and inhibits the PI3K-Akt-mTOR pathway to target leukemia stem cells.

## Key findings

- RPL5 knockdown reduces survival and colony-forming ability of AML cells and inhibits leukemia stem cell engraftment.
- RPL5 deficiency induces ribosomal stress and disrupts the PI3K-Akt-mTOR signaling pathway in leukemia stem cells.
- RPL5 depletion affects transcripts with longer exons and proteins with lower Ile to Val ratios, impacting BCAA metabolism.

## Abstract

Ribosomal protein L5 (RPL5) is considered a haplo-insufficient tumor suppressor by upregulating p53 expression or promoting the inactivation of c-Myc in solid tumors upon tumor initiation. However, its detailed effect and mechanism in tumor maintenance were more complicated. Particularly, the specific role of RPL5 in acute myeloid leukemia (AML) remains unclear. In this study, we found that RPL5 expression was increased in primary AML blasts compared with normal controls, regardless of TP53 mutation. RPL5 knockdown reduced the survival and colony-forming ability of AML cells in vitro, as well as inhibited the engraftment of leukemia stem cells (LSCs) in vivo. It indicated that RPL5 was required for the survival of AML cells, especially for maintaining the stemness of LSCs. The data analysis of RNA-seq and proteomics revealed that RPL5 deficiency eradicated LSC by inducing a cellular stress response, i.e., ribosomal stress, rather than a specific function relating to RPL5. The inhibited PI3K-Akt-mTOR signaling pathway played a central role in the ribosomal stress induced by RPL5 deficiency. To investigate the selectivity of RPL5 depletion in eradicating LSCs, we found that RPL5 expression was highest in LSCs compared to AML cells and healthy controls. Moreover, ribosomal stress specifically affected transcripts with longer exon lengths and proteins with a lower isoleucine (Ile) to valine (Val) ratio. Ile and Val are glycogenic branched-chain amino acids (BCAAs) that regulate fundamental cell processes by affecting mTOR activation through BCAA metabolism. In conclusion, RPL5 depletion-induced ribosomal stress disrupted stemness maintenance by affecting BCAA metabolism in AML, specifically inhibiting the PI3K-Akt-mTOR signaling pathway, which resulted in LSC eradication.

## Linked entities

- **Genes:** RPL5 (ribosomal protein L5) [NCBI Gene 6125], TP53 (tumor protein p53) [NCBI Gene 7157], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Proteins:** RPL5 (ribosomal protein L5), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase)
- **Chemicals:** isoleucine (PubChem CID 791), valine (PubChem CID 1182)
- **Diseases:** acute myeloid leukemia (MONDO:0015667), AML (MONDO:0018874)

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, RPL5 (ribosomal protein L5) [NCBI Gene 6125] {aka L5, MSTP030, PPP1R135, uL18}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** solid tumors (MESH:D009369), AML (MESH:D015470), leukemia (MESH:D007938)
- **Chemicals:** BCAA (MESH:D000597)
- **Mutations:** isoleucine (Ile) to valine (Val)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847885/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847885/full.md

---
Source: https://tomesphere.com/paper/PMC12847885